Subject:
- Active Substance: Asciminib
- Name: Scemblix®
- Therapeutic area: Chronic myeloid leukemia
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 01.10.2022
- Publication of assessment: 02.01.2023
- End of public hearing: 23.01.2023
- Final decision by G-BA: middle of March 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation